Acadia Pharmaceuticals | ACAD - Market Capitalization


Acadia Pharmaceuticals reported $3.38B in Market Capitalization this October of 2026, considering the latest stock price and the number of outstanding shares.





Market Capitalization Change Date
Acadia Pharmaceuticals USD 4.33B 537M Jun/2026
ALKERMES USD 8.73B 2.85B Jun/2026
Alnylam Pharmaceuticals USD 24.65B 15.54B Oct/2026
Biogen USD 35.56B 2.19B Oct/2026
BioMarin Pharmaceutical USD 11.06B 196M Jun/2026
Bristol-Myers Squibb USD 122.14B 4.48B Oct/2026
Cara Therapeutics USD 30M 336M Mar/2026
Corcept Therapeutics USD 9.33B 5.02B Jun/2026
Cytokinetics USD 11.55B 3.36B Jun/2026
Eisai JPY 1.2T 219.32B Jun/2026
Eli Lilly USD 1.3T 171.99B Oct/2026
Incyte USD 25.9B 3.25B Oct/2026
J&J USD 607B 46.61B Oct/2026
Neurocrine Biosciences USD 16.95B 3.7B Jun/2026
Pfizer USD 138.44B 15.37B Jun/2026
Prothena USD 516M 2M Mar/2026
PTC Therapeutics USD 4.94B 1.86B Oct/2026
Sarepta Therapeutics USD 1.9B 388M Jun/2026
Ultragenyx Pharmaceutical USD 3.29B 1.23B Jun/2026
Vanda Pharmaceuticals USD 279M 6M Dec/2024
Vertex Pharmaceuticals USD 126.07B 12.49B Jun/2026